Four simple pragmatic rules are proposed to facilitate the management of essential hypertension in the context of primary care. Rule 1: Abandon diastolic blood pressure measurement and rely on systolic blood pressure values for decisions on treatment thresholds and goals. Rule 2: Assess overall cardiovascular risk by history taking, physical examination and simple investigation (urine dipsticks, serum creatinine, glucose, lipids and ECG). Rule 3: As a generality, apply a systolic threshold of 150 mm Hg for the introduction of drug treatment when
Introduction
In response to increasing demands for the delivery of evidence-based health care, national and international bodies have systematically evaluated the wealth of data derived from epidemiological observational studies and intervention trials and published authoritative guidelines on several aspects of hypertension management. [1] [2] [3] [4] Regrettably, but perhaps inevitably, these have led to inconsistencies in recommendations on treatment thresholds for intervention and goals of treatment advocated by the various bodies, despite reference to a common database. The reasons for the diversity of views are many. The risks associated with particular levels of blood pressure defined by epidemiological surveys in which single casual blood pressures have been measured and related to subsequent cardiovascular risk, may be very different from the risks of the average of a series of blood pressures measured over a period of weeks or months by a physician or practice nurse. MacMahon and colleagues 5 attempted to address this question by estimates of 'usual' blood pressure derived from an historical Framingham database. How valid these estimates are to predict risk in a non-American multi-ethnic contemporary population is unknown. Another cause for confusion is in the interpretation of the extensive trial database 6 on which so many recommendations are made. The intervention trials, which have assessed the long-term benefits of treating hypertension on cardiovascular morbidity and mortality included patients who were not entirely representative of the hypertensive population from which they were drawn, for example, ethnic minority groups were seldom represented and higher risk patients and those with concomitant disease were usually excluded.
In these trials the blood pressure range at entry was often considerably higher than the usual blood pressure of the patients as seen in the control or placebo groups in which there was a substantial fall in blood pressure with time. The real benefits of treatment observed in these trials may therefore be attributable to patients whose blood pressures were actually much lower than at the time of entry. Furthermore, the absolute level of benefit cannot be calculated from these trials because of the intention-totreat policy of data analysis. High-risk patients from the placebo group were removed for ethical reasons. Their blood pressures were treated (and presumably their risk of cardiovascular events reduced), yet they remained in the placebo group for the purpose of analysis.
With these considerations it is thus clear that the evidence on which guidelines for management are based is open to varied interpretation. More recent guidelines 7 have proposed that decisions on management of individuals with hypertension, in particular thresholds of blood pressure to treat, should take into account estimates of absolute cardiovascular risk based for example on the Framingham database. These estimates are influenced by the presence or absence of concomitant risk factors such as lipid profile and the presence or absence of diabetes, and are strongly influenced by the age of the patient. Whilst on scientific grounds this is clearly a step forward, the case for their more widespread implementation, for example in primary health care, has been made by those who have misinterpreted previous guidelines and wrongly claimed that using risk scores would prevent misclassification and undertreatment of sub-groups of patients, eg, those with mild hypertension but concomitant risk. 8 Guidelines based on these assessments are also inconsistent depending on arbitrary and subjective views of the quantitative measure of cardiovascular risk above which treatment is deemed appropriate and which differ for recommendations on blood pressure reduction compared with cholesterol lowering.
As a consequence there is a danger of adding to the serious confusion already prevalent in primary health care practices. They are in my view unnecessary and will not be widely adopted, not least because there is additional criticism of the overriding influence of age and the focus on the quantification of short term risk. This inevitably denies younger people with mild and moderate elevations of blood pressure the facility of treatment which we know from longitudinal studies will not only reduce their chances of developing more severe hypertension but also will improve life expectancy.
This confusion amongst doctors and uncertainties about treatment strategies must be one major explanation underlying the appalling levels of blood pressure control in the United Kingdom and other European countries. 9 The recent Health Survey for England, 10 using the most conservative definitions of control of blood pressure (Ͻ160 mm Hg systolic and Ͻ95 mm Hg diastolic) reports that around 70% of known hypertensives are uncontrolled and clearly subject to high residual cardiovascular risk. Using more recent guidelines for control (Ͻ140 mm Hg systolic and Ͻ90 mm Hg diastolic) the proportion uncontrolled would rise to around 94%. That this is a failure of therapeutic management and not a problem of the disease per se is clear from the observations on the recruitment of patients into hypertension trials where the simple application of goal directed treatment algorithms leads to good blood pressure control in most patients. 11 Those responsible for previous guidelines have consistently failed to communicate the key messages to those who practice medicine. New guidelines on the drawing board, no doubt more sophisticated and comprehensive, will not address this issue and since the old guidelines seem to have had little impact on practice, why should the new ones?
Discussions amongst general practitioners over the past 5 years, since the previous guidelines were published, leads me to conclude that the way forward is to provide simple, clear and practical recommendations which can be readily taken up in primary practice.
I propose that the key issue in hypertension management today in primary care is the treatment of those patients who will benefit from treatment and to ensure that treatment failures are addressed by modification of drug therapy and/or dose to achieve control.
Four simple rules are recommended. 
Rationale
Systolic blood pressure is in general a better predictor of future cardiovascular events than diastolic pressure, 12 added to which diastolic pressure fails to be predictive after taking into account systolic pressure. 13 Moreover, diastolic blood pressure is less acurately assessed than systolic. When systolic blood pressure is elevated it is usually irrelevent for the purpose of decision-making what the diastolic pressure is. The exception is in the case of severe hypertension where high systolic pressure combined with high diastolic pressure (eg, Ͼ125 mm Hg) may indicate accelerated phase or malignant hypertension which constitutes a medical emergency with urgent need for hospitalisation.
Clearly in the elderly, isolated systolic hypertension represents a somewhat different patient subgroup in whom the genesis of the blood pressure elevation is largely explained by reduced compliance of the large arteries. Nevertheless, the decision on whether or not to treat in the elderly should be influenced in virtually all cases by the level of systolic blood pressure irrespective of diastolic. Few physicians treat an elevated diastolic blood pressure in the absence of a raised systolic.
Textbooks of physiology emphasised the constant diastolic load to which the vascular walls were subjected and historically this focus on diastolic blood pressure determined the use of these measurements in making therapeutic decisions.
14 It is recognised that in the presence of a high systolic pressure very high diastolic pressures may predict higher absolute risk, nevertheless, treatment decisions based on systolic pressures and systolic goals still prevail and obviate the need for further consideration of diastolic levels except as mentioned above in the case of malignant hypertension. Cardiovascular risk assessment in the hypertensive should be based on careful examination for evidence of target organ damage (retinal vessels, cardiac enlargement and or failure, cerebral or peripheral vascular pathology) and simple investigations for concomitant risk (diabetes, lipid profile).
The '150' systolic blood pressure rule is a simple, pragmatic and more readily applicable rule than the alternative and often difficult interpretation of the various guidelines on thresholds to treat. Applied simply the threshold of 150 mm Hg systolic pressure is used as a guide threshold for intervention follow-ing repeated measures of blood pressure over a period of weeks or months depending on the severity of the elevation. For low risk uncomplicated patients a more conservative approach may be adopted by raising the threshold to 160 mm Hg. On the other hand, in high risk patients, particularly those with diabetes, the threshold may be lowered to 140 mm Hg, in line with the recommendations of certain bodies. 3, 4, 7 These recommendations are compatible with calculations of risk based on pooled epidemiological data and intervention trial data if 'in-trial' blood pressures are used as the basis for extrapolation, eg, MRC Mild Hypertension Trial. 15 The '150' rule also proposes goal pressures of 150 mm Hg systolic with an option to vary as indicated above for low and high risk patients.
Following the introduction of therapeutic measures, including non-pharmacological treatment, where treatment fails and blood pressure does not fall below the treatment threshold, drug dosage should be increased (except diuretics), treatment changed or combinations of drugs introduced to achieve goal pressures. Therapeutic inertia and the reluctance to alter treatment in the face of poor blood pressure control is the rule rather than the exception, as reported in an extensive survey of European practice, including the UK. Were physicians to achieve a goal systolic pressure of Ͻ150 mm Hg in the majority of their patients this would result in a reduction in their risk of a future cardiovascular event of around 25% and a substantial saving of deaths from heart attacks and strokes.
Perhaps those who challenge these proposals on the grounds of their oversimplification should consider the words of the late Geoffrey Rose: 'One sometimes wishes that Nikolai Korotkoff had not described the fourth and fifth phases . . .' He would have suggested the allocation of two health care regions to one in which the various evidence-based guidelines are distributed and to others where the 150 rule is introduced. I look forward to an audit of outcome on the quality of blood pressure control in these two study environments.
